Glaukos Corp Company Profile (NYSE:GKOS)

Glaukos Corp trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

Glaukos Corp (NYSE:GKOS) announced its quarterly earnings results on Wednesday, March, 1st. The company reported $0.00 EPS for the quarter, beating the consensus estimate of $0.00 by $0.00. The company had revenue of $33.17 million for the quarter, compared to analyst estimates of $29.49 million. Glaukos Corp had a net margin of 2.45% and a return on equity of 2.93%. Glaukos Corp's revenue was up 63.6% compared to the same quarter last year. During the same quarter last year, the business earned ($0.07) earnings per share. View Glaukos Corp's Earnings History.

7 equities research analysts have issued 1 year price targets for Glaukos Corp's shares. Their forecasts range from $41.00 to $55.00. On average, they anticipate Glaukos Corp's stock price to reach $49.20 in the next year. View Analyst Ratings for Glaukos Corp.

Here are some recent quotes from research analysts about Glaukos Corp stock:

• 1. According to Zacks Investment Research, "Glaukos Corporation is an ophthalmic medical technology company. The Company develops, manufactures and markets medical devices for the treatment of glaucoma. Its product pipeline consists of iStent Inject, the iStent Supra and iDose. The company operates primarily in United States, Germany, Europe, the Asia Pacific, Canada and internationally. Glaukos Corporation is headquartered in Laguna Hills, California. " (7/21/2017)
• 2. Cantor Fitzgerald analysts commented, "We are reiterating our Overweight rating on GKOS and raising our price target to $54 from $45, following what we view as impressive 4Q16 results and strong revenue guidance for 2017. Yesterday after the close, Glaukos reported 4Q16 revenues of $33.2 million, beating our revenue estimate of $30.0 million. We note that $2 million of the growth was associated with advanced sales to ASC customers ahead of increased reimbursement changes. Management provided initial 2017 sales guidance of $160-165 million, above our previous estimate of $140 million. We have updated our model to reflect the better-than-anticipated guidance and are extending our NPV out by one year, which is reflected in our increased 12-month price target." (3/2/2017)
• 3. Stifel Nicolaus analysts commented, "Glaukos' stock has considerably outperformed the market YTD (+29% relative to the S&P). We attribute the strong performance to ongoing positive investor sentiment as well as a better understanding of the pricing power that the company possesses in 2017 due to the favorable Ambulatory Surgical Center (ASC) reimbursement decision that took hold at the beginning of the year. While Glaukos does not plan to provide ASP details, our late January diligence among a small number of iStent physicians unveiled that Glaukos is in the midst of implementing a significant price increase (~40%) among iStent cases performed at the ASC. A price increase of this magnitude implies upside to the Street's current 2017 revenue estimate of $147.5MM (we are at $151.4MME), and our January report laid out a case where 2017 revenue could total $180MM+. As investors have better understood the power of price over the past few weeks, we believe the bar has been raised into the company's 2017 guidance, which will be provided on Wednesday (AMC). In this report, we take a near-term look at what different 2017 revenue guidance levels imply for 2017 iStent volumes based on our ASP diligence. We also take a longer-term look at Glaukos' future earnings power, which we view as significant, and believe will become more evident in 2H17 / 1H18. Simply put, we can see 2019 adjusted EBITDA per share (which we use as a proxy for cash EPS) of $2.23 to $3.33, which does not include future pipeline products such as iDose, or the significant market opportunity associated with the stand-alone Glaucoma market." (2/28/2017)

Some companies that are related to Glaukos Corp include Endologix (ELGX), RTI Surgical (RTIX), Cerus Corporation (CERS), ConforMIS (CFMS), Obalon Therptcs (OBLN), Second Sight Medical Products (EYES), Concepta PLC (CPT), Concepta PLC (FRI), Cyberonics (CYBX), HeartWare International (HTWR), St Jude Medical (STJ), Trivascular Technologies (TRIV) and Uroplasty (UPI).

Glaukos Corp's management team includes the folowing people:

• William J. Link Ph.D., Independent Chairman of the Board
• Thomas William Burns, President, Chief Executive Officer and Director
• Joseph E. Gilliam, Chief Financial Officer, Senior Vice President - Corporate Development
• Chris M. Calcaterra, Chief Commercial Officer and Chief Operating Officer
• L. Jay Katz, Chief Medical Officer
• Mark J. Foley, Independent Director
• David F. Hoffmeister, Independent Director
• Gilbert Kliman M.D., Independent Director
• Jonathan Todd Silverstein J.D., Independent Director
• Marc A. Stapley, Independent Director

(GKOS) raised $76 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Glaukos Corp's stock is owned by a number of of retail and institutional investors. Top institutional investors include InterWest Venture Management Co (2.97%), Peregrine Capital Management LLC (0.96%), Handelsbanken Fonder AB (0.41%), Handelsinvest Investeringsforvaltning (0.15%), Bank of Montreal Can (0.05%) and Fox Run Management L.L.C. (0.04%). Company insiders that own Glaukos Corp stock include Aimee S Weisner, Chris M Calcaterra, Jonathan Silverstein, Montreux Equity Partners Iv Lp, Orbimed Advisors Llc, Richard L Harrison, Thomas William Burns and William J Phd Link. View Institutional Ownership Trends for Glaukos Corp.

Glaukos Corp's stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can and Handelsbanken Fonder AB. Company insiders that have sold Glaukos Corp stock in the last year include Chris M Calcaterra, Jonathan Silverstein, Orbimed Advisors Llc, Richard L Harrison, Thomas William Burns and William J Phd Link. View Insider Buying and Selling for Glaukos Corp.

Glaukos Corp's stock was bought by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Handelsinvest Investeringsforvaltning and Fox Run Management L.L.C.. Company insiders that have bought Glaukos Corp stock in the last two years include Aimee S Weisner and Richard L Harrison. View Insider Buying and Selling for Glaukos Corp.

Shares of Glaukos Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Glaukos Corp stock can currently be purchased for approximately $41.31.